Alon Seri-Levy, Sol-Gel Technologies CEO
BridgeBio company sells off rare disease candidate to Galderma partner
Israeli biotech Sol-Gel Technologies announced Friday that it got its hands on a rare disease drug candidate from PellePharm for almost …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
